June 19, 2024

Biologics Contract Development Market Size Analysis 2023 To 2032

The global biologics contract development market size accounted for US$ 6.65 Bn in 2022 and is projected to reach around USD 18.71 Bn by 2032, growing at a CAGR of 10.89% from 2023 to 2032.

Biologics Contract Development Market Size 2023 To 2032

Report Summary

The global biologics contract development market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the biologics contract development market across the globe.

A comprehensive estimate on the biologics contract development market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of biologics contract development during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3056

Biologics Contract Development Market Report Scope 

Report CoverageDetails
Market Size in 2023USD 7.38 Billion
Market Size by 2032USD 18.71 Billion
Growth Rate from 2023 to 2032CAGR of 10.89%
Largest MarketNorth America
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Source, By Product Service, and By Indication
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized biologics contract development market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Spectrometry Market Size To Cross USD 37.48 Bn By 2032

Biologics Contract Development Market Players

The report includes the profiles of key biologics contract development market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Abzena Ltd
  • AGC Biologics
  • Bionova Scientific, Inc.
  • BioXcellence
  • Curia Global, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Genscript
  • KBI Biopharma
  • STC Biologics
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Boehringer Ingelheim Group
  • Samsung Biologics
  • Lonza Group

Market Segmentation

By Source 

  • Microbial
  • Mammalian
  • Others

By Product Service 

  • Cell Line Development
    • Microbial
    • Mammalian
    • Others
  • Process Development
    • Upstream
      • Microbial
      • Mammalian
      • Others
    • Downstream
      • Impurity, isolation, & identification
      • Physicochemical characterization
      • Pharmaceutical analysis
      • Others
    • By Product
      • MABs
      • Recombinant proteins
      • Others
  • Others

By Indication 

  • Oncology
  • Immunological disorders
  • Cardiovascular disorders
  • Hematological disorders
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biologics Contract Development Market 

5.1. COVID-19 Landscape: Biologics Contract Development Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biologics Contract Development Market, By Source

8.1. Biologics Contract Development Market, by Source, 2023-2032

8.1.1 Microbial

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Mammalian

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Biologics Contract Development Market, By Product Service

9.1. Biologics Contract Development Market, by Product Service, 2023-2032

9.1.1. Cell Line Development

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Process Development

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Biologics Contract Development Market, By Indication 

10.1. Biologics Contract Development Market, by Indication, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Immunological disorders

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Cardiovascular disorders

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Hematological disorders

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Biologics Contract Development Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Source (2020-2032)

11.1.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.1.3. Market Revenue and Forecast, by Indication (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Indication (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Source (2020-2032)

11.2.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.2.3. Market Revenue and Forecast, by Indication (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Indication (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Source (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Indication (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Source (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Indication (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Source (2020-2032)

11.3.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.3.3. Market Revenue and Forecast, by Indication (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Indication (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Source (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Indication (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Source (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Indication (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Indication (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Source (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Indication (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Source (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Indication (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.5.3. Market Revenue and Forecast, by Indication (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Source (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Indication (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Source (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Product Service (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Indication (2020-2032)

Chapter 12. Company Profiles

12.1. Abzena Ltd

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. AGC Biologics

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Bionova Scientific, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. BioXcellence

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Curia Global, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Fujifilm Diosynth Biotechnologies

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Genscript

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. KBI Biopharma

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. STC Biologics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com